

Date: 11<sup>th</sup> November, 2022

To,  
The Secretary,  
**The Calcutta Stock Exchange Limited**  
7, Lyons Range,  
Kolkata – 700 001

Dear Sir,

**Sub: Outcome of Board Meeting held on 11<sup>th</sup> November, 2022**

This is to inform you that, Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Director at its meeting was held at its Registered Office on Friday, 11<sup>th</sup> November, 2022 (**commenced at 11:00 AM and concluded at 11.40 A.M.**) have inter-alia considered, approved and adopted the following agenda:

1. Standalone Unaudited Financial Results of the Company for the 02<sup>nd</sup> quarter and half year ended 30<sup>th</sup> September, 2022.
2. Limited Review Report issued by the Statutory Auditors on Standalone Unaudited Financial Results for 02<sup>nd</sup> quarter and half year ended 30<sup>th</sup> September, 2022.
3. The undertaking of non-applicability of Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 is enclosed herewith.

This information is also available on Company's website: [www.adinathbio.com](http://www.adinathbio.com) and on the stock exchange website: [www.cse-india.com](http://www.cse-india.com).

The Company would be publishing Extract of Unaudited Financial Result for the 02<sup>nd</sup> Quarter ended 30-09-2022, in accordance with Regulation 47(1) (b) of the Listing Regulation.

Request you to kindly take the above on record.

Thanking you,

Yours faithfully,

**For Adinath Bio-Labs Limited**

**KISHAN  
SINGH**

**Kishan Singh  
(Whole-Time Director)  
(DIN: 07526266)**

Digitally signed by KISHAN SINGH  
DN: cn=KISHAN SINGH, o=ADINATH BIO-LABS LIMITED, ou=ADINATH BIO-LABS LIMITED, email=KISHAN SINGH@ADINATHBIO.COM, c=IN  
Date: 2022.11.11 11:45:05 +0530



Encl.: As above.

Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2022							
Sr. No.	Particulars	PART I					(Rs. In lakhs)
		Quarter Ended			Half Year Ended		Year Ended
		Unaudited (30/09/2022)	Unaudited (30/06/2022)	Unaudited (30/09/2021)	Unaudited (30/09/2022)	Unaudited (30/09/2021)	Audited (31/03/2022)
<b>1</b>	<b>Income from operations</b>						
	(a) Net Sales / income from operations	-	-	-	-	-	-
	(b) Other Income	-	8.49	0.64	8.49	1.27	5.32
	<b>Total income from operations (net)</b>	-	<b>8.49</b>	<b>0.64</b>	<b>8.49</b>	<b>1.27</b>	<b>5.32</b>
<b>2</b>	<b>Expenses</b>						
	(a) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-	-	-	-	-	-
	(b) Employee benefits expense	1.36	1.36	1.36	2.71	2.71	5.43
	(c) Finance Cost	-	-	-	-	-	-
	(d) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.01	0.01
	(e) Other expenses	1.11	2.64	1.21	3.75	3.73	5.59
	<b>Total expenses</b>	<b>2.47</b>	<b>3.99</b>	<b>2.57</b>	<b>6.46</b>	<b>6.45</b>	<b>11.03</b>
<b>3</b>	<b>Profit / (Loss) from operations before Exceptional &amp; Extraordinary Items (1-2)</b>	<b>(2.47)</b>	<b>4.50</b>	<b>(1.93)</b>	<b>2.03</b>	<b>(5.18)</b>	<b>(5.71)</b>
<b>4</b>	<b>Exceptional &amp; Extraordinary Items</b>	-	-	25.47	-	74.38	99.91
<b>5</b>	<b>Profit / (Loss) before Tax (3 ± 4)</b>	<b>(2.47)</b>	<b>4.50</b>	<b>(27.40)</b>	<b>2.03</b>	<b>(79.56)</b>	<b>(105.63)</b>
<b>6</b>	<b>Tax expense</b>						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
	Earlier Years	-	-	-	-	-	-
	<b>Total Tax Expenses</b>	-	-	-	-	-	-
<b>7</b>	<b>Net Profit/(Loss) after tax(5 ± 6)</b>	<b>(2.47)</b>	<b>4.50</b>	<b>(27.40)</b>	<b>2.03</b>	<b>(79.56)</b>	<b>(105.63)</b>
<b>8</b>	<b>Other Comprehensive Income / (Loss)</b>	-	-	-	-	-	-
<b>9</b>	<b>Total Comprehensive Income / (Loss) ( 7 ± 8 )</b>	<b>(2.47)</b>	<b>4.50</b>	<b>(27.40)</b>	<b>2.03</b>	<b>(79.56)</b>	<b>(105.63)</b>
<b>10</b>	<b>Paid-up equity share capital</b>	2,207.43	2,207.43	2,207.43	2,207.43	2,207.43	2,207.43
	(Face Value in Re.)	1	1	1	1	1	1
<b>11</b>	<b>Earnings Per Share (Not annulised except for year ended)</b>						
	Basic & Diluted	(0.00)	0.00	(0.01)	0.00	(0.04)	(0.05)

**Notes:**

- The above Unaudited Financial results have been reviewed by the Audit committee and adopted by the Board of Directors at their meeting held on 11th November, 2022.
- The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- The company is engaged in the business of Trading and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- The Statutory Auditors of the Company have conducted a limited review of the above unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2022 and issued an unqualified report in this behalf.
- Provisions for income tax and deferred tax will be made at the end of the year except for those which pertain to earlier years on account of any specific order received by the company.
- The accumulated losses have eroded net worth to the extent of 50% of the capital of the Company.
- Previous period's figures corresponding to current period are converted into lakhs.
- Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

By order of the Board  
For Adinath Bio-Labs Limited

KISHAN SINGH  
Mr. Kishan Singh is a Director of Adinath Bio-Labs Limited and is also a Director of Adinath Bio-Labs Limited. He is also a Director of Adinath Bio-Labs Limited. He is also a Director of Adinath Bio-Labs Limited.

Kishan Singh  
 Whole Time Director  
 DIN :07526266



Date: 11th November, 2022  
 Place: Kolkata

Statement of Assets and Liabilities as on 30th September, 2022

(Rs. in lakhs)

Sl. No.	Particulars	As at 30th	As at 31st March,
		September, 2022	2022
		Unaudited	Audited
<b>I</b>	<b>ASSETS</b>		
<b>A</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	0.98	0.99
	(b) Capital work-in-progress	-	-
	(c) Investments Property	-	-
	(d) Goodwill	-	-
	(e) Other Intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological Assets other than bearer plant	-	-
	(h) Financial assets		
	i) Investments	2.88	2.88
	ii) Trade Receivables	-	-
	iii) Loans and Advances	-	-
	iv) Other Non current financial assets	47.43	50.55
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	-	-
	<b>Total Non-current assets</b>	<b>51.29</b>	<b>54.41</b>
<b>B</b>	<b>Current assets</b>		
	(a) Inventories	-	-
	(b) Financial assets		
	i) Investments	-	-
	ii) Trade Receivables	-	-
	iii) Cash and cash equivalents	0.83	1.73
	iv) Loans	25.30	25.30
	v) Other current financial assets	2.36	4.98
	(c) Other current assets	-	-
	(d) Prepayments	-	-
	<b>Total Current assets</b>	<b>28.49</b>	<b>32.00</b>
	<b>TOTAL ASSETS</b>	<b>79.78</b>	<b>86.42</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>		
<b>A</b>	<b>EQUITY SHARE CAPITAL</b>		
	(a) Equity Share capital	2,207.43	2,207.43
	(b) Other Equity	(2,204.62)	(2,206.64)
	<b>Total equity</b>	<b>2.81</b>	<b>0.78</b>
<b>B</b>	<b>LIABILITIES</b>		
<b>I</b>	<b>Non-current liabilities</b>		
	(a) Financial liabilities		
	i) Borrowings	-	-
	ii) Lease Liabilities	-	-
	iii) Trade Payables	-	-
	iv) Other non-current financial liabilities	-	-
	(b) Long term provisions	-	-
	(c) Deferred tax liabilities (net)	-	-
	(d) Other non-current liabilities	-	-
	<b>Total Non-current liabilities</b>	<b>-</b>	<b>-</b>
<b>II</b>	<b>Current liabilities</b>		
	(a) Financial liabilities		
	i) Borrowings	-	-
	ii) Lease Liabilities	-	-
	iii) Trade payables	-	-
	iv) Other current financial liabilities	-	-
	(b) Other current liabilities	0.36	1.16
	(c) Provisions	-	-
	(d) Current tax liabilities	76.61	84.47
	<b>Total Current liabilities</b>	<b>76.97</b>	<b>85.64</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>79.78</b>	<b>86.42</b>

Date: 11th November, 2022  
Place: Kolkata



By order of the Board  
For Adinath Bio-Labs Limited

Kishan Singh  
Whole Time Director  
DIN :07526266

KISHAN  
SINGH

Digitally signed by Kishan Singh  
DN: cn=Kishan Singh, o=Adinath Bio-Labs Limited,  
ou=Adinath Bio-Labs Limited, email=kishan@adinathbio.com,  
c=IN

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2022		
(Rs. In lakhs)		
Particulars	For the Half Year Ended 30th September, 2022	For the Year Ended 31st March, 2022
<b>(A) Cash Flow From Operating Activities</b>		
Net Profit before Tax & Exceptional items	2.03	(5.71)
<b>Adjustments for :-</b>		
Profit on Sale of Fixed Assets	-	(2.79)
Other Income	(8.49)	(2.53)
Depreciation and Amortisation on tangible assets	0.00	0.01
<b>Operating Profit Before Working Capital Changes</b>	<b>(6.46)</b>	<b>(11.02)</b>
<b>Adjustments for :-</b>		
<b>Working/ Operating Capital Changes</b>		
(Increase)/ Decrease in Other Receivables	5.73	8.43
Increase/ (Decrease) in Other Current Liabilities	(0.80)	(1.51)
<b>Cash Generated From Operations</b>	<b>(1.53)</b>	<b>(4.09)</b>
Payment of Taxes	-	-
<b>Net Cash Flow (Used in)/ Generated From Operating Activities (A)</b>	<b>(1.53)</b>	<b>(4.09)</b>
<b>(B) Cash Flow From Investing Activities</b>		
Sales/ (Purchase) of Property, Plants and Equipments (Net)	-	3.25
Interest (Net)	0.63	2.53
<b>Net Cash Flow (Used in)/ Generated From Investing Activities (B)</b>	<b>0.63</b>	<b>5.78</b>
<b>(C) Cash Flow From Financing Activities</b>		
<b>Net Cash Flow (Used in)/ Generated From Financing Activities (C)</b>	-	-
<b>Net Increase / (Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(0.90)</b>	<b>1.69</b>
<b>Cash &amp; Cash Equivalents as at the beginning of the year</b>	<b>1.73</b>	<b>0.04</b>
<b>Cash &amp; Cash Equivalents as at the end of the year</b>	<b>0.83</b>	<b>1.73</b>

By order of the Board  
For Adinath Bio-Labs Limited

KISHAN  
SINGH

Kishan Singh  
Whole Time Director  
DIN :07526266

Date: 11th November, 2022  
Place: Kolkata



**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
The Board of Directors  
Adinath Bio-Labs Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Adinath Bio-Labs Limited** (the "Company") for the quarter and half year ended on 30<sup>th</sup> September, 2022 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KSA & Co.  
Chartered Accountants  
FRN: 003822C



Rasmi Ranjan Jaiswal  
Partner

Membership No.: 511397

UDIN: 22511397-BCUEQY1644

Place: Delhi

Date: 11/11/2022



Date: 11<sup>th</sup> November, 2022

To,  
The Secretary,  
**The Calcutta Stock Exchange Limited**  
7, Lyons Range,  
Kolkata – 700 001

Dear Sir,

**Sub: Non- applicability of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) on a quarterly basis for public issue, rights issue, preferential issue etc..-

- (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;
- (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. Kishan Singh, Whole Time Director of Adinath Biolabs Limited hereby certify that Compliances of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company, as the company has not issued any share by way of public issue, right issue, preferential issue etc. during the quarter ended on 30<sup>th</sup> September, 2022.

You are requested to take the above information in your records.

Thanking you,

Yours faithfully,

**For Adinath Bio-Labs Limited**

**KISHAN  
SINGH**

**Kishan Singh  
(Whole-Time Director)  
DIN: 007526266**

Digitaly signed by KISHAN SINGH  
DN: cn=Kishan Singh, o=Adinath Bio-Labs Limited, ou=Adinath Bio-Labs Limited, email=kishan@adinathbio.com, c=IN  
c=IN, o=Adinath Bio-Labs Limited, ou=Adinath Bio-Labs Limited, email=kishan@adinathbio.com, c=IN  
Date: 2022.11.11 11:46:34 +05'30'

